Congress is ready to get into the craft beer business, which could mean bad news for big batch craft brewers like Sam Adams.
Senator Ron Wyden, a Democrat from Oregon, proposed the new Craft Beverage Modernization and Tax Reform Act that would give the U.S. government the right to define who is and isn’t a craft brewer.
- The craft brewers, those producing under 2 million barrels per year would get the deepest tax cuts.
- The mid-size brewers, those producing 6 million barrels or less, get a slight tax break.
- The macro brewers, which don’t get a tax break beyond their first 6 million barrels of production.
It’s a technicality, essentially a quirk of the law that would group companies for tax purposes. But, it would leave a number of big-name craft brewers out of the first category and in a higher tax bracket. That includes Boston Beer Co., which produces 4.1 million barrels (including non-beer beverages such as Angry Orchard cider and Twisted Tea), as well as Yuengling (2.7 million barrels) and North American Breweries (about 2.6 million barrels) with its Magic Hat, Pyramid and other brands.
Given Boston Beer’s recent production growth, almost 20% per year, it could possibly enter the macro brewer league in less than three years.
Until now, to be labeled a craft beer, breweries had to fit within restrictions designated by the Brewers Association craft beer industry group that involved barrels of production, percentage of a brewery owned by a non-craft brewer and more “traditional” aspects.
The industry self-policer has been somewhat accommodating to its peers in years past. It raised the barrel-production limit to 6 million from 2 million in 2010 to allow Boston Beer to lay claim to the craft beer title.
Boston Beer has been on a production tear in recent years, averaging more than 20% growth annually. If it stays the course, it could possibly reach the 6-million-plus macro brewer league in less than three years, leaving its craft brewing title far behind.
More Must-Read Stories From TIME
- How an Online Pharmacy Sold Millions Worth Of Dubious COVID-19 Drugs — While Patients Paid the Price
- Why Literally Millions of Americans Are Quitting Their Jobs
- Meet the Women Participating in the Study That Could Change Future of Breast Cancer
- Inside the Battle for the Hearts and Minds of Tomorrow's Business Leaders
- An Innovative Washington Law Aims to Get Foreign-Trained Doctors Back in Hospitals
- Why the Ex-Husband of a Missing Chinese Billionaire Is Risking All to Tell Their Story
- Timothée Chalamet Wants You to Wear Your Heart on Your Sleeve